{"DataElement":{"publicId":"13252373","version":"1","preferredName":"Nivolumab During Induction Therapy Permanent Discontinue Yes No Indicator","preferredDefinition":"Yes/No Indicator of whether nivolumab was permanently discontinued during induction therapy.","longName":"13252371v1.00:2015869v3.00","context":"NRG","contextVersion":"1","DataElementConcept":{"publicId":"13252371","version":"1","preferredName":"Nivolumab During Induction Therapy Permanent Discontinue","preferredDefinition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role :At some point in a given period of time._The first choice of treatment for a particular type of cancer._Continuing or enduring over time, without fundamental or marked change._To stop or end, permanently or temporarily.","longName":"2233604v1.00:13252370v1.00","context":"NRG","contextVersion":"1","ObjectClass":{"publicId":"4882031","version":"1","preferredName":"Nivolumab","preferredDefinition":"A fully human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1/PCD-1) with immunopotentiation activity. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands PD-L1 and PD-L2, resulting in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and effector function through the suppression of P13k/Akt pathway activation.","longName":"C68814","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nivolumab","conceptCode":"C68814","definition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"18D28FE9-699E-68CC-E050-BB89AD437B6D","latestVersionIndicator":"Yes","beginDate":"2015-06-18","endDate":null,"createdBy":"NELSONA","dateCreated":"2015-06-18","modifiedBy":"ONEDATA","dateModified":"2015-06-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"13252374","version":"1","preferredName":"During Induction Therapy Permanent Discontinue","preferredDefinition":"At some point in a given period of time._The first choice of treatment for a particular type of cancer._Continuing or enduring over time, without fundamental or marked change._To stop or end, permanently or temporarily.","longName":"C25490:C158876:C160628:C25484","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"During","conceptCode":"C25490","definition":"At some point in a given period of time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Induction Therapy","conceptCode":"C158876","definition":"The first choice of treatment for a particular type of cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Permanent","conceptCode":"C160628","definition":"Continuing or enduring over time, without fundamental or marked change.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Discontinue","conceptCode":"C25484","definition":"To stop or end, permanently or temporarily.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7E3E5F0-557C-6664-E053-731AD00A95A7","latestVersionIndicator":"Yes","beginDate":"2023-03-27","endDate":null,"createdBy":"TSESU","dateCreated":"2023-03-27","modifiedBy":"TSESU","dateModified":"2023-03-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"F7E3BF7B-16F8-61C0-E053-731AD00A4452","latestVersionIndicator":"Yes","beginDate":"2023-03-27","endDate":null,"createdBy":"TSESU","dateCreated":"2023-03-27","modifiedBy":"TSESU","dateModified":"2023-03-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2015869","version":"3","preferredName":"Yes No Indicator","preferredDefinition":"Response of Yes or No to a question.","longName":"YES_NO_IND","context":"CIP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"2567168","version":"1","preferredName":"Yes","longName":"2567168","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D36D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":"12/29/2006 - Updated with NCI Thesaurus definition.","administrativeNotes":"2022.12.29 Alt VM added per ticket request CADSR0001837. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"547F9AF9-A23D-0C88-E044-0003BA3F9857","beginDate":"2008-08-15","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2008-08-15","modifiedBy":"CHILLIJ","dateModified":"2008-08-15","deletedIndicator":"No"},{"value":"No","valueDescription":"No ","ValueMeaning":{"publicId":"2567170","version":"1","preferredName":"No","longName":"2567170","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D36F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-13","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":"Updated to add NCIt concept relationship. Updated VM Short Name to be the Public ID to be consistent with current convention for VM Short Name - DW 10-03-2022","administrativeNotes":"2022.12.29 Alt VM added per ticket request CADSR0001837. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"547F9AF9-A231-0C88-E044-0003BA3F9857","beginDate":"2008-08-15","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2008-08-15","modifiedBy":"CHILLIJ","dateModified":"2008-08-15","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2320047","version":"1","preferredName":"Indicator","preferredDefinition":"An event, entity or condition that typically characterizes a prescribed environment or situation. Indicators determine or aid in determining whether or not certain stated circumstances exist or criteria are satisfied. (On-line Medical Dictionary)","longName":"C25180","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"FC6EF0D8-521A-6865-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-25","modifiedBy":"ONEDATA","dateModified":"2005-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"IVI:caBIG In Vivo Imaging Workspace","workflowStatus":"RELEASED","registrationStatus":"Application","id":"547F9AF9-A1E6-0C88-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-15","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2008-08-15","modifiedBy":"REEVESD","dateModified":"2014-08-17","changeDescription":"8/15/08 - Associated NCIt concets for Yes/No instead of Meta.  Superceded existing VD.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"Was nivolumab permanently discontinued during induction therapy?","url":null,"context":"NRG"},{"name":"NRG CRF Text 1","type":"Alternate Question Text","description":"Did the patient experience any nivolumab-related autoimmune toxicities as outlined in section 6.5 that resulted in permanent discontinuation of nivolumab during the induction treatment phase?","url":null,"context":"NRG"}],"origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"F7E3CF44-D8B2-639F-E053-731AD00A7B26","latestVersionIndicator":"Yes","beginDate":"2023-03-27","endDate":null,"createdBy":"TSESU","dateCreated":"2023-03-27","modifiedBy":"TSESU","dateModified":"2023-03-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}